Publicacións en colaboración con investigadores/as de Thomas Jefferson University (8)

2022

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    The Lancet, Vol. 399, Núm. 10326, pp. 729-740

2020

  1. Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders

    Current Osteoporosis Reports, Vol. 18, Núm. 5, pp. 515-525

  2. Mucopolysaccharidosis IVA: Diagnosis, treatment, and management

    International Journal of Molecular Sciences, Vol. 21, Núm. 4

2017

  1. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

    The Lancet HIV, Vol. 4, Núm. 11, pp. e486-e494

2011

  1. A novel cardioprotective p38-MAPK/mTOR pathway

    Experimental Cell Research, Vol. 317, Núm. 20, pp. 2938-2949

2010

  1. CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell orientation

    Journal of Cell Science, Vol. 123, Núm. 8, pp. 1274-1284

  2. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Núm. 16, pp. 7401-7406

2008

  1. SOK1 translocates from the golgi to the nucleus upon chemical anoxia and induces apoptotic cell death

    Journal of Biological Chemistry, Vol. 283, Núm. 23, pp. 16248-16258